The Breast Friends Podcast shared a post on LinkedIn:
“Why hasn’t immunotherapy consistently delivered in HER2+ disease?
Dr. Paolo Tarantino and Dr. Jason A. Mouabbi discuss a major clinical paradox: HER2 antibodies already “flag” the immune system through ADCC, yet adding formal immunotherapy hasn’t moved the needle. It raises a fascinating question about whether “oncogene-driven” diseases are simply too “clean” for IO to thrive.
We’re watching 2026 data closely for a potential breakthrough.
Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, and Amazon Music
Other articles featuring The Breast Friends Podcast on OncoDaily.